Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Zilebesiran in Japanese Patients with Mild to Moderate Hypertension
jRCT2071240016Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jun 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zilebesiran in hypertension (HTN) (3 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Frequency of Adverse Events (AEs). Started Jun 2024; status: completed.
02
Drugs
zilebesiran
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on jRCT2071240016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240016.